Navigation Links
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
Date:6/9/2008

00 persons or less in the U.S. Orphan drug designation by the FDA allows for seven years of market exclusivity following approval of a New Drug Application, as well as reduced regulatory fees and additional regulatory support for research and development initiatives.

Ted Daley, president of Bennu, stated, "Huntington's Disease is a terrible, debilitating disorder with no current cure. Available drugs can only minimize symptoms, such as uncontrollable movements and mood swings. The FDA's decision to grant cysteamine orphan drug designation in Huntington's Disease complements our efforts to develop additional indications for cysteamine. We will be building off of the existing preclinical data that shows cysteamine's safety and potential efficacy to treat HD. We look forward to initiating a Phase II clinical study in HD patients in 2008."

Dr. Christopher M. Starr, Raptor's Chief Executive Officer, stated, "We are delighted that the FDA has granted orphan drug designation for cysteamine in HD. Our team at Raptor is well-versed in developing and gaining regulatory approval of new therapies for orphan drug disorders. We hope to contribute some of this orphan drug expertise and know-how to facilitate Bennu's clinical program for HD."

Through its acquisition by merger of Encode Pharmaceuticals in December 2007, Bennu obtained an exclusive, worldwide license to the intellectual property rights for the development of cysteamine from UC San Diego for the treatment of certain diseases including cystinosis, non-alcoholic steatohepatitis ("NASH") and Huntington's disease.

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp.'s business consists of two segments: its 100% ownership of development stage biotechnology company Raptor Pharmaceutical Inc. ("Raptor Inc."); and its 100% ownership of clinical-stage development company Bennu. Raptor Inc. bioengineers novel drug candidates and drug- targeting platforms derived from the human recep
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... (PRWEB) May 27, 2015 Expanding in ... cement manufacturer Avalon Biomed Inc. recently inked ... Mokuda Dental Co. Ltd. , the largest endodontic ... into the international market for Avalon Biomed, which manufactures ... award-winning tricalcium silicate-based dental cements that have won renown ...
(Date:5/27/2015)... Israel , May 27, 2015  Tikcro Technologies ... quarter ended March 31, 2015. ... quarter, we continued pre-clinical work to generate functional specific ... an early stage, we are encouraged by the development ... field as new antibodies which modulate immune checkpoints gain ...
(Date:5/27/2015)... Winnipeg, MB (PRWEB) May 27, 2015 ... imaging data to combat disease, Cubresa Inc. today ... , “Our MR Compatible in-bore PET Scanner uses ... inserted into single-purpose preclinical MRI machines from manufacturers ... of Cubresa, headquartered in Winnipeg, Canada. “This enables ...
(Date:5/27/2015)... BETHESDA, Md. , May 27, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for cancer, ... Chief Technical Officer of the Company, will be making ... Annual Meeting in Chicago on ... CDT, at the Industry Expert Theater in McCormick Place. ...
Breaking Biology Technology:Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3Cubresa Launches Simultaneous PET/MRI Technology 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3
... 21 Accuray,Incorporated (Nasdaq: ARAY ), a global ... president and chief executive officer, Euan S.,Thomson, Ph.D., is ... Care Conference at the Pierre Hotel in New York ... (9:30 a.m. PST)., A live webcast of the ...
... 21 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... officer and chairman of Trubion, is scheduled to ... Markets Healthcare Investor,Conference to be held at The ... present Nov. 27, 2007, at 2:30 p.m. Interested ...
... 21 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... live during the 19th Annual Piper Jaffray,Health Care ... p.m. Eastern,Time. The presentation will be webcast from ... under the Investor Relations tab at http://www.alexza.com ...
Cached Biology Technology:Accuray Incorporated's CEO to Speak at Piper Jaffray 19th Annual Health Care Conference 2Accuray Incorporated's CEO to Speak at Piper Jaffray 19th Annual Health Care Conference 3Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference 219th Annual Piper Jaffray Health Care Conference to Webcast Alexza's Corporate Presentation 2
(Date:5/28/2015)... , May 28, 2015 Industry analyst ... a new report titled "Markets for Self-Healing Materials: ... inorganic capsule and vascular systems, biomaterials, relevant shape ... to around $2.7 billion by 2020. ... extensive coverage of smart materials. Other recent n-tech reports ...
(Date:5/27/2015)... CLEVELAND , May 27, 2015 /PRNewswire/ ... in medication safety systems and image documentation ... provider of comprehensive, technologically-advanced automation solutions, is ... art integration. The Codonics® Safe Label System® ... used in conjunction with the Omnicell Anesthesia ...
(Date:5/26/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/p2kc6z/saudi_arabia ... "Saudi Arabia Biometric Systems Market Forecast and Opportunities, ... http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market in ... grow at over 22% CAGR through 2020 ... surging demand for better biometric technologies in the ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2
... Scientists at the University of Maryland and Tulane University ... that is the first to address the interaction of ... research team simulated how the fish,s flexible body bends, ... around it as well as the muscles inside. Understanding ...
... at the University of Michigan Heath System and their ... one day help guide new treatments for psoriasis, one ... Using cutting-edge methods to peer into the ... the research, published in Nature Genetics, further ...
... agreement between the MPI of Biochemistry and GSK pursues ... research and development work is based on the research ... Biochemistry. He and fellow scientist Mathias Bcker successfully described ... kinases - in connection with the development of type ...
Cached Biology News:Computational model of swimming fish could inspire design of robots or medical prosthetics 2Computational model of swimming fish could inspire design of robots or medical prosthetics 3Four new psoriasis 'hotspots' identified by U-M geneticists 2Cooperation in diabetes research 2
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
cysteine and glycine-rich protein 2,...
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
Biology Products: